Teclison Ltd.
Teclison Limited is dedicated to transforming cancer treatment by developing innovative therapies that induce tumor necrosis and enhance antitumor immunity. Their platform radically remodels the tumor immune microenvironment of solid cancers, aiming to improve the effectiveness of immunotherapies and achieve long-term remission for patients with metastatic solid tumor cancers.
Industries
Nr. of Employees
small (1-50)
Teclison Ltd.
100 Overlook Center 2nd Floor Princeton, NJ 08540, USA; 7-1, No. 57, Fuxing N. Road, Songshan District Taipei, Taiwan, R.O.C. 105404
Patents
Products
TEC-001
TEC-001 with transarterial embolization (TATE) uses a procedure to shut off blood supply to the tumor, creating a hypoxic environment necessary for drug activation. It works with immune checkpoint inhibitors (ICIs) to generate a systemic anticancer immune response.
TEC-002
TEC-002 converts solid tumors into an environment suitable for TEC-001 activation, potentially treating nearly all solid tumor indications without the need for TATE.
TATE Platform Therapy
A therapy that induces tumor necrosis and boosts anticancer immunity by creating a hypoxic environment in the tumor, enhancing the efficacy of immune checkpoint inhibitors (ICIs).
TEC-001
TEC-001 with transarterial embolization (TATE) uses a procedure to shut off blood supply to the tumor, creating a hypoxic environment necessary for drug activation. It works with immune checkpoint inhibitors (ICIs) to generate a systemic anticancer immune response.
TEC-002
TEC-002 converts solid tumors into an environment suitable for TEC-001 activation, potentially treating nearly all solid tumor indications without the need for TATE.
TATE Platform Therapy
A therapy that induces tumor necrosis and boosts anticancer immunity by creating a hypoxic environment in the tumor, enhancing the efficacy of immune checkpoint inhibitors (ICIs).
Services
Engagement and collaboration with external organizations for research, development, and investment related to oncology therapeutic programs.
Engagement and collaboration with external organizations for research, development, and investment related to oncology therapeutic programs.
Expertise Areas
- Immuno-oncology
- Tumor immune microenvironment modulation
- Combination therapy development with immune checkpoint inhibitors
- Liver-metastatic solid tumor therapeutics
Key Technologies
- Tumor immune microenvironment modulation
- Immuno-oncology therapeutics
- Combination therapy with immune checkpoint inhibitors
- Tumor necrosis induction mechanisms